GoAI
Get started
Stablecoin Development Corp. logo

Stablecoin Development Corp.

SDEV

AMEXHealthcareMedical - Pharmaceuticals

Open in GoAI

Previous close

$1.13

+$0.01 · +0.89%

Aug 21, 3:59 PM ET

SDEV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

83

Deep Value

Momentum

19

Strong Down

Sentiment

49

Mixed

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
US
CEO
Michael Kazley
Listed since
Oct 26, 2007
Employees
4

Market position

Day range

Current $1.13

52-week range

Current $1.13

Open
$1.25
Previous close
$1.12
Volume
8.17M
11.18× average
Average volume
731.22K
Average daily volume
Market cap
57.01M USD
Beta
0.09
Market reference 1
50-day average
$1.945
-41.90% below average
200-day average
$1.945
-41.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
34.8K USD
P/E (TTM)
0.08×
P/B (TTM)
0.28×
P/S (TTM)
12.21×
EV / EBITDA
-0×
Earnings yield
-8895.63%
Free cash flow yield
-116.81%
Dividend yield
353.98%

Profitability & efficiency

Gross margin
98.99%
Operating margin
-141.12%
Net margin
10354.34%
Return on equity
2812.49%
Return on assets
-6030.25%
Return on invested capital
-75.90%

Financial health

Debt / equity
0×
Current ratio
7.39×
Altman Z-score
123.25
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends79%19%-42%-102%Gross margin, FY2021: 63.85%Gross margin, FY2022: 54.02%Gross margin, FY2023: 58.19%Operating margin, FY2021: -86.85%Operating margin, FY2022: -53.32%Operating margin, FY2023: -39.23%Net margin, FY2021: -57.08%Net margin, FY2022: -73.65%Net margin, FY2023: -58.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.85%. Gross margin FY2022 54.02%. Gross margin FY2023 58.19%. Operating margin FY2021 -86.85%. Operating margin FY2022 -53.32%. Operating margin FY2023 -39.23%. Net margin FY2021 -57.08%. Net margin FY2022 -73.65%. Net margin FY2023 -58.78%.

Income trends

Revenue

10.46M USD-27.42%

Operating income

−7.59M USD-2.79%

Net income

−641.98M USD-8788.00%
Income trends across reported periods80.04M USD−182.51M USD−445.06M USD−707.62M USDRevenue, FY2021: 10.2M USDRevenue, FY2022: 14.4M USDRevenue, FY2023: 10.46M USDOperating income, FY2021: −8.86M USDOperating income, FY2022: −7.68M USDOperating income, FY2023: −4.1M USDOperating income, FY2024: −7.38M USDOperating income, FY2025: −7.59M USDNet income, FY2021: −5.82M USDNet income, FY2022: −10.61M USDNet income, FY2023: −6.15M USDNet income, FY2024: −7.22M USDNet income, FY2025: −641.98M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.2M USD. Revenue FY2022 14.4M USD. Revenue FY2023 10.46M USD. Operating income FY2021 −8.86M USD. Operating income FY2022 −7.68M USD. Operating income FY2023 −4.1M USD. Operating income FY2024 −7.38M USD. Operating income FY2025 −7.59M USD. Net income FY2021 −5.82M USD. Net income FY2022 −10.61M USD. Net income FY2023 −6.15M USD. Net income FY2024 −7.22M USD. Net income FY2025 −641.98M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue——10.46M USD14.4M USD10.2M USD
Cost of goods sold140K USD341K USD4.37M USD6.62M USD3.69M USD
Gross profit−140K USD−341K USD6.08M USD7.78M USD6.52M USD
Research and development—42K USD34K USD174K USD44K USD
Selling, general, and administrative7.45M USD7.04M USD10.15M USD15.29M USD15.33M USD
Operating expenses7.45M USD7.04M USD10.19M USD15.46M USD15.38M USD
Interest expense277K USD904K USD1.69M USD——
Depreciation and amortization140K USD341K USD356K USD483K USD119K USD
Operating income−7.59M USD−7.38M USD−4.1M USD−7.68M USD−8.86M USD
Net income−641.98M USD−7.22M USD−6.15M USD−10.61M USD−5.82M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
20%
2 beats, 7 misses, 1 met estimate
Average EPS surprise
-233.84%
10 comparable reports
Latest EPS result
0.01
Estimate -0.55 · Beat by 101.82%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.98-7.12-16.23-25.33Q4 '24MissQ2 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q4 2024, reported Nov 7, 2024: actual -3, estimate -1.53, surprise -96.72%, Miss. Q2 2025, reported Apr 2, 2025: actual -23.45, estimate -1.2, surprise -1854.17%, Miss. Q2 2025, reported May 15, 2025: actual -3.33, estimate -1.2, surprise -177.50%, Miss. Q3 2025, reported Aug 14, 2025: actual -1.65, estimate -1.05, surprise -57.14%, Miss. Q4 2025, reported Nov 7, 2025: actual -1.15, estimate -1.05, surprise -9.52%, Miss. Q2 2026, reported May 15, 2026: actual 0.1, estimate -1, surprise +110.00%, Beat. Q3 2026, reported Jul 30, 2026: actual 0.01, estimate -0.55, surprise +101.82%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.6, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.06M2.86M1.65M442.85KQ4 '24MissQ2 '25MissQ2 '25EstimateQ3 '25EstimateQ4 '25MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q4 2024, reported Nov 7, 2024: actual 2.44M USD, estimate 2.6M USD, surprise -6.12%, Miss. Q2 2025, reported Apr 2, 2025: actual 2.31M USD, estimate 2.5M USD, surprise -7.64%, Miss. Q2 2025, reported May 15, 2025: actual —, estimate 3M USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual —, estimate 3M USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 7, 2025: actual 521K USD, estimate 3M USD, surprise -82.63%, Miss. Q2 2026, reported May 15, 2026: actual 2.46M USD, estimate 3.6M USD, surprise -31.58%, Miss. Q3 2026, reported Jul 30, 2026: actual 2.21M USD, estimate 3.3M USD, surprise -33.15%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 3.8M USD, surprise —, Comparison unavailable.

SDEV news

defenseworld.net

Stablecoin Development (NYSEAMERICAN:SDEV) Stock Price Passes Below 200 Day Moving Average – What’s Next?

Stablecoin Development Corporation (NYSEAMERICAN:SDEV - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.93…

Read source
globenewswire.com

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

Abbott Cooper PLLC is investigating fiduciary duty claims for SDEV (formerly NovaBay Pharmaceuticals) holders who owned shares before August 19, 2025.

Read source
globenewswire.com

Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results

Staking revenue of $2.2 million for the quarter and $4.7 million for the first half of 2026 SDEV grew its SKY position to 2.29 billion tokens (approximately 10% of total SKY supply) and eliminated all remaining warrant…

Read source
globenewswire.com

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders

STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Stablecoin Development Corporation (Nasdaq: SDEV) (formerly NovaBay…

Read source

Corporate actions

Corporate action history

Dividend

Ex-dividend Sep 30, 2025

$4.00

Special

Record Sep 15, 2025

SDEV peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

-1.41%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

+2.80%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

-1.38%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

0.00%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

+0.08%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

0.00%

ETFs holding SDEV

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
498.54K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
324.28K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research SDEV

research.disclaimer